Literature DB >> 21993544

hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas.

Yi Wang1, Hongmei Luo, Yangle Li, Tieding Chen, Shengpeng Wu, Luoyan Yang.   

Abstract

Numerous microRNAs (miRNAs) play crucial roles in cancer development. In this study, we report that hsa-miR-96 is expressed at higher levels in human bladder urothelial carcinomas compared to normal tissues. We found that hsa-miR-96 increased invasion and differentiation of human bladder T24 cells and promoted their growth. Down‑regulation of hsa-miR-96 significantly affected the phenotype of bladder cancer T24 cells. The mRNA and protein levels of insulin receptor substrate 1 (IRS1) and MAP4K1 were significantly reduced in cells transfected with the hsa-miR-96 inhibitor when compared with levels in cells transfected with the empty plasmid vector or the negative control miRNA inhibitor. Altogether, these results suggest that hsa-miR-96 may affect the growth of bladder cancer cells by up-regulating IRS1 and MAP4K1 levels, functioning as a promising diagnostic marker in human bladder urothelial carcinomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993544     DOI: 10.3892/mmr.2011.621

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  33 in total

1.  Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.

Authors:  Emmanuel I Papadopoulos; George M Yousef; Andreas Scorilas
Journal:  Tumour Biol       Date:  2015-04-02

2.  Evaluation of urinary miRNA-96 as a potential biomarker for bladder cancer diagnosis.

Authors:  Sanaa Eissa; Haidy Habib; Esraa Ali; Yossif Kotb
Journal:  Med Oncol       Date:  2014-12-16       Impact factor: 3.064

3.  Long non-coding RNA MEG3 suppresses the development of bladder urothelial carcinoma by regulating miR-96 and TPM1.

Authors:  Guanghua Liu; Xin Zhao; Jingmin Zhou; Xiangming Cheng; Zixing Ye; Zhigang Ji
Journal:  Cancer Biol Ther       Date:  2018-11-21       Impact factor: 4.742

4.  Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.

Authors:  Emmanuel I Papadopoulos; Andreas Scorilas
Journal:  Clin Transl Sci       Date:  2015-09-10       Impact factor: 4.689

Review 5.  MicroRNAs: Key Players in Bladder Cancer.

Authors:  Qi Li; Helei Wang; Hourong Peng; Qiuping Huang; Ting Huyan; Qingsheng Huang; Hui Yang; Junling Shi
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

6.  Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis.

Authors:  Sanaa Eissa; Marwa Matboli; Nada O E Essawy; Youssef M Kotb
Journal:  Tumour Biol       Date:  2015-07-03

7.  MicroRNA-96 expression induced by low-dose cisplatin or doxorubicin regulates chemosensitivity, cell death and proliferation in gastric cancer SGC7901 cells by targeting FOXO1.

Authors:  Chunhui Lang; Miao Xu; Ziyi Zhao; Jinyao Chen; Lishi Zhang
Journal:  Oncol Lett       Date:  2018-07-11       Impact factor: 2.967

8.  DLX6-AS1 promotes cell proliferation, migration and EMT of gastric cancer through FUS-regulated MAP4K1.

Authors:  Qiong Wu; Jiali Ma; Wenying Meng; Pingping Hui
Journal:  Cancer Biol Ther       Date:  2019-10-08       Impact factor: 4.742

Review 9.  MicroRNAs and lung cancers: from pathogenesis to clinical implications.

Authors:  Ji Qi; David Mu
Journal:  Front Med       Date:  2012-04-18       Impact factor: 4.592

Review 10.  The evolving understanding of microRNA in bladder cancer.

Authors:  Elizabeth A Guancial; Joaquim Bellmunt; Shuyuan Yeh; Jonathan E Rosenberg; David M Berman
Journal:  Urol Oncol       Date:  2013-08-02       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.